Oncaspar (pegaspargase) is a long-acting prescription injection medicine used for people with a type of blood cancer known as acute lymphoblastic leukemia (ALL). It is also approved specifically for ...
Chemotherapy for pediatric acute lymphoblastic leukemia (ALL) induces rapid and durable alterations in cerebrospinal fluid (CSF) metabolism, and a lipid-rich CSF signature measured early in treatment ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...
A new cell therapy, targeting CD7 on leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment ...
Survival rates for childhood leukemia are improving thanks to new treatments. Acute lymphoblastic leukemia has the highest survival among all pediatric cancers, 80-85 percent. Seattle Children’s ...
In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...
Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without ...
Asparlas (calaspargase pegol-mknl) is a long-acting prescription injection medicine used for people with a certain type of blood cancer known as acute lymphoblastic leukemia (ALL). It is approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results